Double maintains 2 strategies that include PRAX - Praxis Precision Medicines, Inc.
Current Value
$77.651 Year Return
Current Value
$77.651 Year Return
Finnhub
Three blockbuster-potential assets in late-stage clinical trials and four pivotal readouts expected in 2025; anticipate four commercial assets by 2028 Study 1 of Essential3 program for ulixacaltamide...
Yahoo
BOSTON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be presenting a corporate overview at the 43rd Annual J.P. Morgan Healthcare Conference taking place in San Francisco, CA at the Westin St. Francis Hotel on Wednesday, Janu
SeekingAlpha
Praxis Precision Medicines, Inc., a promising clinical stage biopharma concern, has seen significant stock gains in the second half of 2024. Read more here.
Yahoo
Dravet syndrome is a genetic developmental and epileptic encephalopathy (DEE) often caused by a mutation in SCN1A This is the third Rare Pediatric Disease Designation for relutrigine, adding to those granted for SCN2A and SCN8A DEEs Praxis plans to initiate an all-DEE trial (EMERALD), inclusive of Dravet syndrome, in 1H2025 BOSTON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the de
Yahoo
BOSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be participating in two upcoming investor conferences in December 2024. Praxis management will be participating in a fireside chat at the Piper Sandler 36th Annual Healthca
Yahoo
BOSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that that it will present preclinical and clinical data from three of its epilepsy programs at the American Epilepsy Society (AES) Annual Meeting, being held from December 6 to 10, 2024
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
TCTM | -12.34% | $2.49M | -72.13% | 0.00% |
MRK | -12.29% | $244.44B | -19.56% | 3.22% |
CVX | -11.76% | $280.36B | +5.01% | 4.16% |
K | -11.43% | $28.19B | +49.68% | 2.77% |
GPRK | -10.79% | $479.39M | +2.74% | 6.05% |
TEN | -10.48% | $528.15M | -25.63% | 8.38% |
MVO | -9.98% | $84.87M | -38.60% | 17.96% |
FLG | -9.34% | $3.90B | -69.34% | 0.87% |
CAG | -9.19% | $12.10B | -14.62% | 5.52% |
ARLP | -9.16% | $3.70B | +30.41% | 9.53% |
HELE | -9.04% | $1.49B | -46.07% | 0.00% |
HIHO | -9.02% | $8.54M | -3.00% | 6.19% |
STNG | -8.98% | $2.54B | -30.59% | 3.34% |
PSQH | -8.94% | $186.23M | -20.15% | 0.00% |
APA | -8.89% | $8.70B | -26.62% | 4.23% |
HSY | -8.52% | $30.33B | -20.84% | 3.69% |
BG | -8.52% | $10.98B | -11.06% | 3.43% |
INSW | -8.26% | $1.82B | -20.55% | 1.29% |
GDS | -7.71% | $4.01B | +257.41% | 0.00% |
ASC | -7.69% | $482.85M | -27.74% | 9.33% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
STOK | 38.62% | $561.45M | +119.01% | 0.00% |
SYRE | 37.11% | $1.28B | -19.22% | 0.00% |
ZYME | 36.86% | $1.03B | +43.60% | 0.00% |
XNCR | 35.07% | $1.43B | +3.18% | 0.00% |
CRNX | 34.10% | $3.64B | +5.23% | 0.00% |
KYMR | 33.99% | $2.86B | +38.91% | 0.00% |
IDYA | 33.90% | $2.01B | -45.20% | 0.00% |
ARVN | 32.91% | $1.24B | -52.34% | 0.00% |
AVDL | 32.72% | $765.11M | -42.13% | 0.00% |
MRSN | 32.19% | $64.29M | -83.58% | 0.00% |
KRYS | 32.14% | $4.46B | +28.48% | 0.00% |
TRU | 31.67% | $18.71B | +38.21% | 0.44% |
IGMS | 31.60% | $102.28M | -83.90% | 0.00% |
ATXS | 31.49% | $426.08M | -23.35% | 0.00% |
NTLA | 31.38% | $1.15B | -55.00% | 0.00% |
DNUT | 31.34% | $1.49B | -36.05% | 2.01% |
ACLX | 31.18% | $3.54B | +10.20% | 0.00% |
VYGR | 30.82% | $302.08M | -27.33% | 0.00% |
MSA | 30.28% | $6.48B | -0.75% | 1.21% |
KALV | 30.18% | $432.41M | -31.91% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CRMT | 0.02% | $401.08M | -23.37% | 0.00% |
CNQ | -0.02% | $66.73B | -1.82% | 6.11% |
VITL | 0.04% | $1.98B | +200.40% | 0.00% |
PAA | 0.04% | $14.47B | +28.24% | 6.16% |
MGPI | 0.07% | $789.66M | -59.13% | 1.34% |
VIPS | -0.08% | $6.27B | -9.72% | 2.97% |
XGN | -0.09% | $70.37M | +106.74% | 0.00% |
QNTM | -0.11% | $6.33M | -93.83% | 0.00% |
SBLK | 0.18% | $1.76B | -30.75% | 16.76% |
CHRD | 0.18% | $7.38B | -20.94% | 6.73% |
CRBG | 0.18% | $18.57B | +31.72% | 2.80% |
RDDT | -0.19% | $31.95B | +435.26% | 0.00% |
KR | 0.20% | $42.38B | +26.15% | 2.09% |
EPM | -0.22% | $187.80M | -3.29% | 8.48% |
GUG | 0.24% | - | - | 9.11% |
HAL | 0.24% | $24.57B | -24.41% | 2.41% |
HRL | 0.27% | $16.94B | +1.45% | 3.69% |
NGL | -0.27% | $728.71M | +0.55% | 0.00% |
CIVI | 0.33% | $5.03B | -17.58% | 3.80% |
USM | 0.33% | $5.35B | +39.70% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
PTH | 41.40% | $123.48M | 0.6% |
XBI | 38.74% | $6.27B | 0.35% |
RSPA | 37.80% | $275.22M | 0% |
IWC | 35.90% | $982.44M | 0.6% |
PINK | 35.90% | $142.14M | 0.5% |
PBE | 34.91% | $254.98M | 0.58% |
ARKG | 34.72% | $1.21B | 0.75% |
XPH | 34.49% | $167.55M | 0.35% |
IWO | 34.19% | $13.09B | 0.24% |
SHLD | 33.85% | $709.84M | 0.5% |
ISCG | 33.84% | $668.38M | 0.06% |
GNOM | 33.81% | $69.64M | 0.5% |
XAR | 33.57% | $2.93B | 0.35% |
FINX | 33.46% | $326.84M | 0.68% |
ARKX | 33.18% | $313.63M | 0.75% |
IBB | 32.62% | $6.39B | 0.45% |
KOMP | 32.18% | $2.20B | 0.2% |
VBK | 31.81% | $20.49B | 0.07% |
FNY | 31.73% | $403.97M | 0.7% |
ARKQ | 31.71% | $1.04B | 0.75% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VRIG | -0.20% | $1.21B | 0.3% |
FTGC | 0.24% | $2.39B | 1.02% |
IEO | 0.33% | $606.96M | 0.4% |
FENY | 0.34% | $1.58B | 0.084% |
IYE | -0.35% | $1.34B | 0.39% |
VDE | 0.44% | $8.03B | 0.1% |
DBA | 0.44% | $828.49M | 0.93% |
KMLM | 0.52% | $326.67M | 0.9% |
BILS | 0.55% | $3.36B | 0.1356% |
FBY | -0.62% | $168.28M | 0.99% |
XLE | -0.66% | $35.24B | 0.09% |
DRLL | -0.71% | $318.00M | 0.41% |
RSPG | 0.90% | $568.46M | 0.4% |
IXC | 0.92% | $1.99B | 0.41% |
BCI | -1.05% | $1.38B | 0.26% |
CMDY | 1.09% | $296.68M | 0.28% |
FCG | 1.11% | $468.63M | 0.6% |
CCOR | -1.32% | $81.54M | 1.18% |
PXE | 1.35% | $107.23M | 0.63% |
FTXN | 1.43% | $170.23M | 0.6% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
TPMN | -20.73% | $34.23M | 0.65% |
VIXY | -18.15% | $195.31M | 0.85% |
SGOV | -14.72% | $31.97B | 0.09% |
UUP | -13.71% | $634.18M | 0.77% |
CTA | -13.61% | $569.44M | 0.76% |
USDU | -10.75% | $397.66M | 0.5% |
TAIL | -10.03% | $64.78M | 0.59% |
TBLL | -9.52% | $1.98B | 0.08% |
UNG | -8.52% | $664.75M | 1.06% |
DBE | -7.61% | $50.17M | 0.77% |
DBO | -7.57% | $208.65M | 0.77% |
XHLF | -7.39% | $955.89M | 0.03% |
GSG | -6.28% | $1.06B | 0.75% |
COMT | -6.13% | $715.33M | 0.48% |
BILZ | -5.94% | $631.56M | 0.14% |
WEAT | -5.36% | $123.99M | 0.28% |
SHV | -4.84% | $19.07B | 0.15% |
MINT | -4.75% | $12.26B | 0.35% |
XBIL | -4.54% | $653.80M | 0.15% |
FLOT | -3.26% | $8.12B | 0.15% |